Abstract
Lung adenocarcinoma (LUAD) is the major type of lung cancer and is one of the deadliest cancers worldwide. IL4I1, as a gene associated with unsatisfactory prognosis, is involved in tumor immune escape, but its immune regulatory mechanism in LUAD is limited. Bioinformatics analysis was applied to analyze the differentially expressed mRNAs and enriched signaling pathways in LUAD tissue. Quantitative real-time polymerase chain reaction (qRT-PCR) was manipulated to test IL4I1 expression. We carried out several methods to examine cell functions: CCK-8 to measure LUAD cell proliferation; flow cytometry to determine cell apoptosis; Western blot to assess the expression of JAK/STAT pathway-related proteins and PD-L1; T cell cytotoxicity assay to evaluate the effect of IL4I1 on the immune escape of LUAD cells. Through bioinformatics analysis, IL4I1 was verified to be highly expressed in LUAD tissue, participate in the modulation of JAK/STAT signaling pathway, and be positively associated with CD274 (PD-L1) expression. Cell function experiments indicated that silencing IL4I1 notably repressed LUAD cell proliferation and induced apoptosis. IL4I1 silence would block JAK/STAT signaling pathway, but this effect could be reversed by RO8191 activator treatment. Moreover, IL4I1 silence suppressed PD-L1 expression and facilitated T cell cytotoxicity, while its inhibitory impact on PD-L1 expression and immune escape of LUAD cells could be reversed by atezolizumab treatment. Overall, we confirmed that IL4I1 promoted the malignant cell behaviors and immune escape of LUAD through JAK/STAT signaling pathway. IL4I1 has the potential to be a diagnostic biomarker for LUAD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data and materials in this current study are available from the corresponding author on reasonable request.
References
Agathangelidis A, Vlachonikola E, Davi F, Langerak AW, Chatzidimitriou A (2022) High-throughput immunogenetics for precision medicine in cancer. Semin Cancer Biol 84:80–88. https://doi.org/10.1016/j.semcancer.2021.10.009
Ai L, Xu A, Xu J (2020) Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol 1248:33–59. https://doi.org/10.1007/978-981-15-3266-5_3
Boulland ML et al (2007) Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood 110:220–227. https://doi.org/10.1182/blood-2006-07-036210
Carbonnelle-Puscian A et al (2009) The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 23:952–960. https://doi.org/10.1038/leu.2008.380
Cao M, Chen W (2019) Epidemiology of lung cancer in China. Thorac Cancer 10:3–7. https://doi.org/10.1111/1759-7714.12916
Chen N et al (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 10:910–923. https://doi.org/10.1097/JTO.0000000000000500
Copie-Bergman C et al (2003) Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 101:2756–2761. https://doi.org/10.1182/blood-2002-07-2215
Denisenko TV, Budkevich IN, Zhivotovsky B (2018) Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 9:117. https://doi.org/10.1038/s41419-017-0063-y
Dreussi E, Ecca F, Scarabel L, Gagno S, Toffoli G (2018) Immunogenetics of prostate cancer: a still unexplored field of study. Pharmacogenomics 19:263–283. https://doi.org/10.2217/pgs-2017-0163
Groner B, von Manstein V (2017) Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol 451:1–14. https://doi.org/10.1016/j.mce.2017.05.033
Huang AC et al (2019) A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 25:454–461. https://doi.org/10.1038/s41591-019-0357-y
Huang W et al (2020) IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer. J Cell Mol Med 24:13949–13960. https://doi.org/10.1111/jcmm.16003
Kong T et al (2020) CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res 80:444–457. https://doi.org/10.1158/0008-5472.CAN-19-1108
Liu XS, Mardis ER (2017) Applications of immunogenomics to cancer. Cell 168:600–612. https://doi.org/10.1016/j.cell.2017.01.014
Liu C et al (2020) Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ 27:1765–1781. https://doi.org/10.1038/s41418-019-0460-0
Liu W, Dong C, Liu X (2021) The role of IL4I1 in immunoregulation: an update. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 37:79–83
Mazzoni A et al (2021) IL4I1 is expressed by head-neck cancer-derived mesenchymal stromal cells and contributes to suppress T cell proliferation. J Clin Med 10. https://doi.org/10.3390/jcm10102111
Mimura K et al (2018) PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 109:43–53. https://doi.org/10.1111/cas.13424
Qing X et al (2020) LINC00669 insulates the JAK/STAT suppressor SOCS1 to promote nasopharyngeal cancer cell proliferation and invasion. J Exp Clin Cancer Res 39:166. https://doi.org/10.1186/s13046-020-01674-z
Ramspott JP et al (2018) Emerging role of IL-4-induced gene 1 as a prognostic biomarker affecting the local T-cell response in human cutaneous melanoma. J Invest Dermatol 138:2625–2634. https://doi.org/10.1016/j.jid.2018.06.178
Sadik A et al (2020) IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 182:1252–1270 e1234. https://doi.org/10.1016/j.cell.2020.07.038 (2020).
Sun LL et al (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307–1316
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7–H1 (PD-L1) in the treatment of advanced human cancer–response. Clin Cancer Res 19:5542. https://doi.org/10.1158/1078-0432.CCR-13-2234
Toshifumi D et al (2017) The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep 37:1545–1554. https://doi.org/10.3892/or.2017.5399
Tsoukalas N et al (2019) PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. J BUON 24:883–888
Wang Y et al (2020) Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan. Cancer Biol Ther 21:1179–1190. https://doi.org/10.1080/15384047.2020.1838032
Wang Z, Li T, Mao C, Liu W, Tao Y (2021) IL4I1-driven AHR signature: a new avenue for cancer therapy. Signal Transduct Target Ther 6:118. https://doi.org/10.1038/s41392-021-00529-z
Weinstock C (2017) U.S. Food and Drug Administration approval summary. Clin Cancer Res 23:4534–4539. https://doi.org/10.1158/1078-0432.CCR-17-0540
Yi L, Wu G, Guo L, Zou X, Huang P (2020) Comprehensive analysis of the PD-L1 and immune infiltrates of m(6)A RNA methylation regulators in head and neck squamous cell carcinoma. Mol Ther Nucleic Acids 21:299–314. https://doi.org/10.1016/j.omtn.2020.06.001
Yue Y et al (2015) IL4I1 is a novel regulator of M2 macrophage polarization that can inhibit T cell activation via L-tryptophan and arginine depletion and IL-10 production. PLoS ONE 10:e0142979. https://doi.org/10.1371/journal.pone.0142979
Zhang X et al (2017) PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol 22:1026–1033. https://doi.org/10.1007/s10147-017-1161-7
Zheng X, Zhu Y, Wang X, Hou Y, Fang Y (2021) Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway. Ann Transl Med 9:803. https://doi.org/10.21037/atm-21-1669
Zhu D et al (2019) Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway. Cancer Med 8:6064–6081. https://doi.org/10.1002/cam4.2494
Author information
Authors and Affiliations
Contributions
All authors contributed to data analysis, drafting, and revising the article, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Ethics approval and consent to participation
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhu, J., Li, Y. & Lv, X. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma. Immunogenetics 75, 17–25 (2023). https://doi.org/10.1007/s00251-022-01275-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-022-01275-4